TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models

References

• Anderson KV, Bokla L, Nüsslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 1985; 42:791-8; PMID:3931919; http://dx.doi.org/10.1016/0092-8674(85)90275-2
   PubMed Web of Science ®Google Scholar
• Taguchi T, Mitcham JL, Dower SK, Sims JE, Testa JR. Chromosomal localization of TIL, a gene encoding a protein related to the Drosophila transmembrane receptor Toll, to human chromosome 4p14. Genomics 1996; 32:486-8; PMID:8838819; http://dx.doi.org/10.1006/geno.1996.0150
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7; PMID:9237759; http://dx.doi.org/10.1038/41131
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-50; PMID:21616434; http://dx.doi.org/10.1016/j.immuni.2011.05.006
   PubMed Web of Science ®Google Scholar
• Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9:293-307; PMID:20380038; http://dx.doi.org/10.1038/nrd3203
   PubMed Web of Science ®Google Scholar
• Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277:15028-34; PMID:11836257; http://dx.doi.org/10.1074/jbc.M200497200
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2014; 21:69-78; PMID:23811849; http://dx.doi.org/10.1038/cdd.2013.72
   PubMed Web of Science ®Google Scholar
• Ozato K, Tsujimura H, Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques 2002; Suppl:66-8, 70, 72 passim; PMID:12395929
   PubMedGoogle Scholar
• Sato Y, Goto Y, Narita N, Hoon DS. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron 2009; 2 Suppl 1:205-14; PMID:19685283; http://dx.doi.org/10.1007/s12307-009-0022-y
   PubMedGoogle Scholar
• Coley WB. II. Hawkins on tubercular peritonitis. Ann Surg 1893; 17:462-4; PMID:17859910; http://dx.doi.org/10.1097/00000658-189301000-00101
   PubMedGoogle Scholar
• Onier N, Hilpert S, Arnould L, Saint-Giorgio V, Davies JG, Jeannin JF. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis 1999; 17:299-306; PMID:10545016; http://dx.doi.org/10.1023/A:1006663017149
   PubMed Web of Science ®Google Scholar
• Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563:1-17; PMID:17383632; http://dx.doi.org/10.1016/j.ejphar.2007.02.018
   PubMed Web of Science ®Google Scholar
• Zhang YB, He FL, Fang M, Hua TF, Hu BD, Zhang ZH, Cao Q, Liu RY. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 2009; 36:1475-81; PMID:18763053; http://dx.doi.org/10.1007/s11033-008-9338-9
   PubMed Web of Science ®Google Scholar
• Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-4; PMID:17615358; http://dx.doi.org/10.1126/science.1140485
   PubMed Web of Science ®Google Scholar
• Yoo KH, Lim TJ, Chang SG. Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute. Exp Ther Med 2012; 3:221-5; PMID:22969872; http://dx.doi.org/10.3892/etm.2011.400
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
   PubMed Web of Science ®Google Scholar
• Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlán G, Silfverdal SA, Szüts P, O'Mahony M, David MP, Dobbelaere K et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health 2012; 50:38-46; PMID:22188832; http://dx.doi.org/10.1016/j.jadohealth.2011.10.009
   PubMed Web of Science ®Google Scholar
• Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661-3; PMID:23264929; http://dx.doi.org/10.4161/onci.22033
   PubMed Web of Science ®Google Scholar
• Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer 2013; 13:172; PMID:23547558; http://dx.doi.org/10.1186/1471-2407-13-172
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
   PubMed Web of Science ®Google Scholar
• D'Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol 2005; 5:1205-12; PMID:15914325; http://dx.doi.org/10.1016/j.intimp.2005.02.013
   PubMedGoogle Scholar
• De Ridder M, Verovski VN, Chiavaroli C, Van den Berge DL, Monsaert C, Law K, Storme GA. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. Int J Radiat Oncol Biol Phys 2006; 66:1473-80; PMID:17056198; http://dx.doi.org/10.1016/j.ijrobp.2006.07.1381
   PubMed Web of Science ®Google Scholar
• Seignez C, Martin A, Rollet CE, Racoeur C, Scagliarini A, Jeannin JF, Bettaieb A, Paul C. Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils. Oncotarget 2014; 5:11442-51; PMID:25347345; http://dx.doi.org/10.18632/oncotarget.2556
   PubMed Web of Science ®Google Scholar
• Gautier T, Paul C, Deckert V, Desrumaux C, Klein A, Labbe J, Le Guern N, Athias A, Monier S, Hammann A et al. Innate immune response triggered by triacyl lipid A is dependent on phospholipid transfer protein (PLTP) gene expression. FASEB J 2010; 24:3544-54; PMID:20418497; http://dx.doi.org/10.1096/fj.09-152876
   PubMed Web of Science ®Google Scholar
• Maitra SK, Schotz MC, Yoshikawa TT, Guze LB. Determination of lipid A and endotoxin in serum by mass spectroscopy. Proc Natl Acad Sci U S A 1978; 75:3993-7; PMID:16592555; http://dx.doi.org/10.1073/pnas.75.8.3993
   PubMed Web of Science ®Google Scholar
• Martin E, Nathan C, Xie QW. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J Exp Med 1994; 180:977-84; PMID:7520478; http://dx.doi.org/10.1084/jem.180.3.977
   PubMed Web of Science ®Google Scholar
• Misko TP, Highkin MK, Veenhuizen AW, Manning PT, Stern MK, Currie MG, Salvemini D. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem 1998; 273:15646-53; PMID:9624158; http://dx.doi.org/10.1074/jbc.273.25.15646
   PubMed Web of Science ®Google Scholar
• Xia Y, Roman LJ, Masters BS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem 1998; 273:22635-9; PMID:9712892; http://dx.doi.org/10.1074/jbc.273.35.22635
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696
   PubMed Web of Science ®Google Scholar
• Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65:5009-14; PMID:15958541; http://dx.doi.org/10.1158/0008-5472.CAN-05-0784
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, Szyfter W, Zeromski J, Whiteside TL. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69:3105-13; PMID:19318560; http://dx.doi.org/10.1158/0008-5472.CAN-08-3838
   PubMed Web of Science ®Google Scholar
• Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007; 67:10519-27; PMID:17974996; http://dx.doi.org/10.1158/0008-5472.CAN-07-0079
   PubMed Web of Science ®Google Scholar
• Núñez NG, Andreani V, Crespo MI, Nocera DA, Breser ML, Morón G, Dejager L, Libert C, Rivero V, Maccioni M. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res 2012; 72:592-603; http://dx.doi.org/10.1158/0008-5472.CAN-11-0534
   PubMed Web of Science ®Google Scholar
• Gauthier N, Lohm S, Touzery C, Chantôme A, Perette B, Reveneau S, Brunotte F, Juillerat-Jeanneret L, Jeannin JF. Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis 2004; 25:1559-65; PMID:15059928; http://dx.doi.org/10.1093/carcin/bgh158
   PubMed Web of Science ®Google Scholar
• Sun J, Druhan LJ, Zweier JL. Dose dependent effects of reactive oxygen and nitrogen species on the function of neuronal nitric oxide synthase. Archives of biochemistry and biophysics 2008; 471:126-33; PMID:18201545; http://dx.doi.org/10.1016/j.abb.2008.01.003
   PubMed Web of Science ®Google Scholar
• Wu G, Morris SM, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336 (Pt 1):1-17; PMID:9806879; http://dx.doi.org/10.1042/bj3360001
   PubMed Web of Science ®Google Scholar
• Feun LG, Kuo MT, Savaraj N. Arginine deprivation in cancer therapy. Curr Opin Clin Nutr Metab Care 2015; 18:78-82; PMID:25474015; http://dx.doi.org/10.1097/MCO.000000000000-0122
   PubMed Web of Science ®Google Scholar
• Gautier T, Klein A, Deckert V, Desrumaux C, Ogier N, Sberna AL, Paul C, Le Guern N, Athias A, Montange T et al. Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. J Biol Chem 2008; 283:18702-10; PMID:18458077; http://dx.doi.org/10.1074/jbc.M802802200
   PubMed Web of Science ®Google Scholar